[
  {
    "ts": "2025-12-08T06:30:00+00:00",
    "headline": "OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development",
    "summary": "OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment NANTES, France, December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammati",
    "url": "https://finance.yahoo.com/news/ose-immunotherapeutics-announces-strategic-amendment-063000041.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "98812cad-0b21-3dcd-8443-fa28548bb85f",
      "content": {
        "id": "98812cad-0b21-3dcd-8443-fa28548bb85f",
        "contentType": "STORY",
        "title": "OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development",
        "description": "",
        "summary": "OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment NANTES, France, December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammati",
        "pubDate": "2025-12-08T06:30:00Z",
        "displayTime": "2025-12-08T06:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/30f72419d0291606fc6eb96fa53d5067",
          "originalWidth": 3189,
          "originalHeight": 1063,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G57RQkdfRqxD8fSqS10JEQ--~B/aD0xMDYzO3c9MzE4OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/30f72419d0291606fc6eb96fa53d5067.cf.webp",
              "width": 3189,
              "height": 1063,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CMuCyX2VYx6bKd3LOJUC.A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/30f72419d0291606fc6eb96fa53d5067.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ose-immunotherapeutics-announces-strategic-amendment-063000041.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ose-immunotherapeutics-announces-strategic-amendment-063000041.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OSE.PA"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T15:53:00+00:00",
    "headline": "Top-Ranked ETFs to Power Your Portfolio Higher",
    "summary": "With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.",
    "url": "https://finance.yahoo.com/news/top-ranked-etfs-power-portfolio-155300843.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f11c9697-fdcf-3435-9c72-3509bf095225",
      "content": {
        "id": "f11c9697-fdcf-3435-9c72-3509bf095225",
        "contentType": "STORY",
        "title": "Top-Ranked ETFs to Power Your Portfolio Higher",
        "description": "",
        "summary": "With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.",
        "pubDate": "2025-12-08T15:53:00Z",
        "displayTime": "2025-12-08T15:53:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/09147180af9fd4afaa322c5ac4332f4b",
          "originalWidth": 620,
          "originalHeight": 356,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nPZ_xEl63p_OAePi2f9LxQ--~B/aD0zNTY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/09147180af9fd4afaa322c5ac4332f4b.cf.webp",
              "width": 620,
              "height": 356,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QBGlpmygme_9thU3DtyI0w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/09147180af9fd4afaa322c5ac4332f4b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-ranked-etfs-power-portfolio-155300843.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-ranked-etfs-power-portfolio-155300843.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "SHW"
            },
            {
              "symbol": "XLF"
            },
            {
              "symbol": "XLB"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "NEM"
            },
            {
              "symbol": "NEMCL"
            },
            {
              "symbol": "BRK-B"
            },
            {
              "symbol": "V"
            },
            {
              "symbol": "XLK"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T19:07:12+00:00",
    "headline": "How Investors May Respond To AbbVie (ABBV) Expanding Its Pipeline With New Migraine And Oncology Data",
    "summary": "In recent weeks, AbbVie has reported positive clinical and regulatory updates across several franchises, including strong Phase 3 migraine data for atogepant, encouraging early-stage blood cancer results for PVEK, and expanded Canadian reimbursement for SKYRIZI in ulcerative colitis. Together with an amended development arrangement for the early-stage antibody ABBV-230, these developments highlight how AbbVie is broadening its pipeline beyond its established immunology and neuroscience...",
    "url": "https://finance.yahoo.com/news/investors-may-respond-abbvie-abbv-190712274.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e4b61ebf-95ac-3218-a9d1-e2b20df62a7f",
      "content": {
        "id": "e4b61ebf-95ac-3218-a9d1-e2b20df62a7f",
        "contentType": "STORY",
        "title": "How Investors May Respond To AbbVie (ABBV) Expanding Its Pipeline With New Migraine And Oncology Data",
        "description": "",
        "summary": "In recent weeks, AbbVie has reported positive clinical and regulatory updates across several franchises, including strong Phase 3 migraine data for atogepant, encouraging early-stage blood cancer results for PVEK, and expanded Canadian reimbursement for SKYRIZI in ulcerative colitis. Together with an amended development arrangement for the early-stage antibody ABBV-230, these developments highlight how AbbVie is broadening its pipeline beyond its established immunology and neuroscience...",
        "pubDate": "2025-12-08T19:07:12Z",
        "displayTime": "2025-12-08T19:07:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-may-respond-abbvie-abbv-190712274.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-may-respond-abbvie-abbv-190712274.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T23:12:32+00:00",
    "headline": "Why The Narrative Around AbbVie Is Shifting After New Immunology And Valuation Updates",
    "summary": "AbbVie’s latest narrative update leaves its fair value estimate steady at roughly $243.55 per share, even as small tweaks to the model reflect a slightly higher discount rate, a touch softer revenue growth outlook, and a modestly lower future valuation multiple applied to earnings. These shifts echo a market balancing act between enthusiasm over durable immunology growth, extended Rinvoq exclusivity, and sector rerating potential, and caution around pipeline execution risks, legacy asset...",
    "url": "https://finance.yahoo.com/news/why-narrative-around-abbvie-shifting-231232940.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "133d36c2-6d02-3fdf-ad9b-32552b2fad24",
      "content": {
        "id": "133d36c2-6d02-3fdf-ad9b-32552b2fad24",
        "contentType": "STORY",
        "title": "Why The Narrative Around AbbVie Is Shifting After New Immunology And Valuation Updates",
        "description": "",
        "summary": "AbbVie’s latest narrative update leaves its fair value estimate steady at roughly $243.55 per share, even as small tweaks to the model reflect a slightly higher discount rate, a touch softer revenue growth outlook, and a modestly lower future valuation multiple applied to earnings. These shifts echo a market balancing act between enthusiasm over durable immunology growth, extended Rinvoq exclusivity, and sector rerating potential, and caution around pipeline execution risks, legacy asset...",
        "pubDate": "2025-12-08T23:12:32Z",
        "displayTime": "2025-12-08T23:12:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-narrative-around-abbvie-shifting-231232940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-narrative-around-abbvie-shifting-231232940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T22:45:02+00:00",
    "headline": "AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know",
    "summary": "AbbVie (ABBV) concluded the recent trading session at $223.12, signifying a -1.31% move from its prior day's close.",
    "url": "https://finance.yahoo.com/news/abbvie-abbv-falls-more-steeply-224502849.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "edb70bbd-fe9d-3c20-9207-f39176605d0d",
      "content": {
        "id": "edb70bbd-fe9d-3c20-9207-f39176605d0d",
        "contentType": "STORY",
        "title": "AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know",
        "description": "",
        "summary": "AbbVie (ABBV) concluded the recent trading session at $223.12, signifying a -1.31% move from its prior day's close.",
        "pubDate": "2025-12-08T22:45:02Z",
        "displayTime": "2025-12-08T22:45:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmhBrL1RMEs5kGBSUQzx5g--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CMWRvhn58nUVOwpQjtvr2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-abbv-falls-more-steeply-224502849.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-abbv-falls-more-steeply-224502849.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]